Danish Biotech Weekly – Week 22

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, Evaxion announced promising phase I data for its cancer vaccine, several companies presented their first quarter results and some got their price targets updated.

10 of the 20 listed, Danish biotech companies have published news the past week. Only 6 of the 20 companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Curasight has become the best performing stock this year.

Company news the past week

Ascendis Pharma

Ascendis Pharma to Host Oncology Program Update on May 31 (Link)

Biosergen

No news the past week

Cessatech

No news the past week

CS Medica

CS MEDICA Onboards distributors with first-year orders of DKK 5.6M and cash flow positively effect by shorter lead times (Link)

Curasight

Curasight: Interim report Q1 2023 (Link)

Evaxion Biotech

Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01 (Link)

Expres2ion

No news the past week

Fluoguide

FluoGuide awarded prestigious grant together with two academic partners (Link)

FluoGuide provides update on strong clinical trial progress (Link)

Genmab

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress (Link)

Gubra

No news the past week

Initiator Pharma

No news the past week

IO Biotech

Jefferies raises price target to $12 from $10

Pila Pharma

No news the past week

Saniona

Saniona publishes its interim report for the first quarter of 2023 (Link)

Scandion Oncology

SCANDION ONCOLOGY – INTERIM REPORT Q1 2023 (Link)

SynAct Pharma

No news the past week

ViroGates

No news the past week

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

Y-mAbs’ Danyelza (naxitamab-gqgk) For Treatment Of High-Risk Neuroblastoma Approved In Brazil (Link)

2cureX

2cureX publishes interim report for the first quarter of 2023 (Link)

SELECTED CASES

SHARE PRICE DEVELOPMENTS

The majority of the Danish Biotech stocks delivered a negative share price performance last week. The average return was -2%. Curasight rose 21% following its Q1 report. Pila Pharma AB also performed well with 11% increase without presenting any news. On the other hand, Saniona AB, Biosergen AB, Cessatech A/S, and Y-mAbs Therapeutics Inc. all fell by more than 10%. Year to date a few companies have delivered excellent returns. Curasight A/S, Fluoguide A/S and Saniona AB have risen by 89-140% after among other things partnerships and positive recommendations paving the way for approvals.

Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment

Overview of share price developments the past week, year-to-date and last twelve months

Disclaimer 

Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra Nyemission.dk)   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.




Investornetværk:

Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email